NCT04902859

Brief Summary

Preterm infants are at risk of developing ROP (retinopathy of prematurity), an eye condition that can cause blindness. Preterm infants born before gestation week (GA) 30 are therefor screened regularly with eye examinations. These eye examinations are painful and despite a lot of research no clear method of pain relief have been found. Since pain in the preterm infant can lead to both short- and longterm negative consequences an effective pain relief during these examinations are of importance. In this study we will investigate if Clonidine can be effective as pain-relief during ROP eye examinations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2022

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 21, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 26, 2021

Completed
11 months until next milestone

Study Start

First participant enrolled

April 25, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

May 4, 2022

Status Verified

April 1, 2022

Enrollment Period

2.7 years

First QC Date

May 21, 2021

Last Update Submit

April 28, 2022

Conditions

Keywords

retinopathy of prematurityprocedural painneonatal

Outcome Measures

Primary Outcomes (1)

  • PIPP-R

    Pain assessment scale

    Within 30 sec after procedure started

Secondary Outcomes (1)

  • GSR

    Within 30 sec after procedure started

Study Arms (4)

Clonidine with eye speculum

EXPERIMENTAL

4 mcg/kg Clonidine given orally in GI-tube.

Drug: Clonidine Oral Liquid Product

Placebo with eye speculum

PLACEBO COMPARATOR

Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.

Drug: Sterile water

Clonidine without eye speculum

EXPERIMENTAL

4 mcg/kg Clonidine given orally in GI-tube.

Drug: Clonidine Oral Liquid Product

Placebo without eye speculum

PLACEBO COMPARATOR

Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.

Drug: Sterile water

Interventions

Clonidine prepared from pharmacy with 20 mcg/ml concentration.

Clonidine with eye speculumClonidine without eye speculum

Sterile water used as placebo

Placebo with eye speculumPlacebo without eye speculum

Eligibility Criteria

Age5 Weeks - 3 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Infants born before 30 weeks gestation, informed consent from parents

You may not qualify if:

  • Infants that have received other pain relieving or sedating drugs within 24 hours before the procedure, infants without GI-tube, infants with neurological deficit, infants with known heart arrhythmia, infants with circulatory instability (MAP below GA in weeks)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barn- och Ungdomskliniken, Universitetssjukhuset

Örebro, Sweden

RECRUITING

Related Publications (1)

  • Carlsen Misic M, Eriksson M, Normann E, Pettersson M, Blomqvist Y, Olsson E. Clonidine as analgesia during retinopathy of prematurity screening in preterm infants (cloROP): protocol for a randomised controlled trial. BMJ Open. 2022 Sep 22;12(9):e064251. doi: 10.1136/bmjopen-2022-064251.

MeSH Terms

Conditions

Retinopathy of PrematurityPain, Procedural

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Miriam Pettersson, MD, PhD

CONTACT

Emma Olsson, RN, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
None of the above will be aware of study drug or placebo.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2021

First Posted

May 26, 2021

Study Start

April 25, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

May 4, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations